Astrazeneca Korea Co. Ltd. will pull its blockbuster diabetes drug, Forxiga (dapagliflozin), from the South Korean market, a company official confirmed to BioWorld, citing “multiple factors” like ...
AstraZeneca’s SGLT2 diabetes drug Forxiga has another approval to celebrate. The drug, known as Farxiga in the U.S., gained a nod in Europe to treat patients suffering from heart failure with any type ...
The European Commission (EC) approved AstraZeneca (NASDAQ:AZN) Forxiga for expanded use to treat heart failure (HF) with reduced ejection fraction (HFrEF) to cover patients across the full spectrum of ...
(RTTNews) - AstraZeneca (AZN, AZN.L) announced Forxiga has been approved in the European Union to extend the indication for heart failure with reduced ejection fraction to cover patients across the ...
(RTTNews) - AstraZeneca (AZN.L, AZN) said its Forxiga has been recommended for approval in the European Union to extend the indication for heart failure with reduced ejection fraction to cover ...
(RTTNews) - AstraZeneca (AZN.L, AZN), on Monday, announced that its Forxiga (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved in China to reduce the risk of ...
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended an additional indication for dapagliflozin (Forxiga ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results